Tumor-associated fibroblasts predominantly come from local and not circulating precursors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 27, 2016, Pages 7551-7556

  Arina, Ainhoa ^a   Idel, Christian ^a,b   Hyjek, Elizabeth M ^a   Alegre, Maria Luisa ^a   Wang, Ying ^a   Bindokas, Vytautas P ^a   Weichselbaum, Ralph R ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Bone marrow; Collagen; Mesenchymal; Origin; Stroma

Indexed keywords

COLLAGEN TYPE 1; EXPRESSING GREEN FLUORESCENT REPOTER PROTEIN; GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG; ACTIN; ALPHA-SMOOTH MUSCLE ACTIN, MOUSE; ENHANCED GREEN FLUORESCENT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER GRAFT; CELLULAR DISTRIBUTION; CIRCULATING TUMOR CELL; CONFOCAL MICROSCOPY; FIBROBLAST; IN VIVO STUDY; INTESTINE TUMOR; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PARABIOSIS; PRECURSOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR ASSOCIATED FIBROBLAST; TUMOR CELL; TUMOR CELL INOCULATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; CANCER ASSOCIATED FIBROBLAST; EXPERIMENTAL NEOPLASM; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ACTINS; ANIMALS; CANCER-ASSOCIATED FIBROBLASTS; CELL LINE, TUMOR; COLLAGEN TYPE I; GREEN FLUORESCENT PROTEINS; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL;

EID: 84977490719     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1600363113     Document Type: Article

References (68)

1. Metchnikoff E (1892) Leçons sur la pathologie comparée de l'inflammation. Faites à l'Institut Pasteur en Avril et Mai 1891 (Masson, Paris).
2. Maximov A (1928) Culture of blood leukocytes. From lymphocytes and monocytes to connective tissue. Arch Exp Zellforsch 5:169-268.
3. Friedenstein A (1989) Stromal-hematopoietic interrelationships: Maximov's ideas and modern models. Haematol Blood Transfus 32:159-167.
4. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A (1994) Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1(1): 71-81.
5. Labat ML, et al. (1991) Cystic fibrosis: Production of high levels of uromodulin-like protein by HLA-DR blood monocytes differentiating towards a fibroblastic phenotype. Biomed Pharmacother 45(9):387-401.
6. Kuwana M, et al. (2003) Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol 74(5):833-845.
7. Abe R, Donnelly SC, Peng T, Bucala R, Metz CN (2001) Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites. J Immunol 166(12):7556-7562.
8. Phillips RJ, et al. (2004) Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 114(3):438-446.
9. LaRue AC, et al. (2006) Hematopoietic origins of fibroblasts: I. In vivo studies of fibroblasts associated with solid tumors. Exp Hematol 34(2):208-218.
10. Reddy K, Zhou Z, Schadler K, Jia SF, Kleinerman ES (2008) Bone marrow subsets differentiate into endothelial cells and pericytes contributing to Ewing's tumor vessels. Mol Cancer Res 6(6):929-936.
11. Spaeth EL, et al. (2009) Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4(4):e4992.
12. Quante M, et al. (2011) Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19(2):257-272.
13. Chang HY, et al. (2002) Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 99(20):12877-12882.
14. Sági B, et al. (2012) Positional identity of murine mesenchymal stem cells resident in different organs is determined in the postsegmentation mesoderm. Stem Cells Dev 21(5):814-828.
15. Higuchi Y, et al. (2015) Gastrointestinal fibroblasts have specialized, diverse transcriptional phenotypes: A comprehensive gene expression analysis of human fibroblasts. PLoS One 10(6):e0129241.
16. Mukudai S, et al. (2015) Differential responses to steroid hormones in fibroblasts from the vocal fold, trachea, and esophagus. Endocrinology 156(3):1000-1009.
17. Flaberg E, et al. (2012) The architecture of fibroblast monolayers of different origin differentially influences tumor cell growth. Int J Cancer 131(10):2274-2283.
18. Klein G (2014) Evolutionary aspects of cancer resistance. Semin Cancer Biol 25:10-14.
19. Klein-Goldberg A, Maman S, Witz IP (2014) The role played by the microenvironment in site-specific metastasis. Cancer Lett 352(1):54-58.
20. Paget S (1889) Distribution of secondary growths in cancer of the breast. Lancet 133(3421):571-573.
21. Cormack DH (2001) Essential Histology (Lippincott Williams & Wilkins, Philadelphia), 2nd Ed.
22. Roufosse C, et al. (2006) Bone marrow-derived cells do not contribute significantly to collagen I synthesis in a murine model of renal fibrosis. J Am Soc Nephrol 17(3): 775-782.
23. Magness ST, Bataller R, Yang L, Brenner DA (2004) A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 40(5):1151-1159.
24. Kalluri R, Zeisberg M (2006) Fibroblasts in cancer. Nat Rev Cancer 6(5):392-401.
25. De Wever O, Demetter P, Mareel M, Bracke M (2008) Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123(10):2229-2238.
26. Polanska UM, Orimo A (2013) Carcinoma-associated fibroblasts: Non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol 228(8):1651-1657.
27. Schietinger A, et al. (2013) Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. OncoImmunology 2(11):e26677.
28. Morikawa S, et al. (2009) Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. J Exp Med 206(11):2483-2496.
29. Moser AR, Pitot HC, Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247(4940):322-324.
30. De Palma M, et al. (2005) Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3):211-226.
31. Cortez-Retamozo V, et al. (2012) Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA 109(7):2491-2496.
32. Purhonen S, et al. (2008) Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci USA 105(18):6620-6625.
33. McGee HM, et al. (2013) IL-22 promotes fibroblast-mediated wound repair in the skin. J Invest Dermatol 133(5):1321-1329.
34. Ross R, Everett NB, Tyler R (1970) Wound healing and collagen formation. VI. The origin of the wound fibroblast studied in parabiosis. J Cell Biol 44(3):645-654.
35. Lin SL, Kisseleva T, Brenner DA, Duffield JS (2008) Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 173(6):1617-1627.
36. Barisic-Dujmovic T, Boban I, Clark SH (2010) Fibroblasts/myofibroblasts that participate in cutaneous wound healing are not derived from circulating progenitor cells. J Cell Physiol 222(3):703-712.
37. Rinkevich Y, et al. (2015) Skin fibrosis. Identification and isolation of a dermal lineage with intrinsic fibrogenic potential. Science 348(6232):aaa2151.
38. Kojima Y, et al. (2010) Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 107(46):20009-20014.
39. Hughes CC (2008) Endothelial-stromal interactions in angiogenesis. Curr Opin Hematol 15(3):204-209.
40. Huet E, et al. (2008) Extracellular matrix metalloproteinase inducer/CD147 promotes myofibroblast differentiation by inducing alpha-smooth muscle actin expression and collagen gel contraction: Implications in tissue remodeling. FASEB J 22(4):1144-1154.
41. Berthod F, Germain L, Tremblay N, Auger FA (2006) Extracellular matrix deposition by fibroblasts is necessary to promote capillary-like tube formation in vitro. J Cell Physiol 207(2):491-498.
42. Morikawa S, et al. (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160(3):985-1000.
43. Dickhut A, et al. (2005) Mesenchymal stem cells obtained after bone marrow transplantation or peripheral blood stem cell transplantation originate from host tissue. Ann Hematol 84(11):722-727.
44. Bartsch K, et al. (2009) Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used. Transplantation 87(2):217-221.
45. Crisan M, et al. (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3):301-313.
46. Caplan AI (2008) All MSCs are pericytes? Cell Stem Cell 3(3):229-230.
47. He Q, Wan C, Li G (2007) Concise review: Multipotent mesenchymal stromal cells in blood. Stem Cells 25(1):69-77.
48. Wexler SA, et al. (2003) Adult bone marrow is a rich source of human mesenchymal 'stem' cells but umbilical cord and mobilized adult blood are not. Br J Haematol 121(2):368-374.
49. da Silva Meirelles L, Chagastelles PC, Nardi NB (2006) Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci 119(Pt 11):2204-2213.
50. Direkze NC, et al. (2004) Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res 64(23):8492-8495.
51. Spiotto MT, Rowley DA, Schreiber H (2004) Bystander elimination of antigen loss variants in established tumors. Nat Med 10(3):294-298.
52. Zhang B, Karrison T, Rowley DA, Schreiber H (2008) IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 118(4):1398-1404.
53. Schüler T, Körnig S, Blankenstein T (2003) Tumor rejection by modulation of tumor stromal fibroblasts. J Exp Med 198(10):1487-1493.
54. Ostermann E, et al. (2008) Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 14(14):4584-4592.
55. Huang S, et al. (2011) Evaluation of the tumor targeting of a FAPα-based doxorubicin prodrug. J Drug Target 19(7):487-496.
56. Olive KP, et al. (2009) Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324(5933):1457-1461.
57. Provenzano PP, et al. (2012) Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21(3): 418-429.
58. Hofheinz RD, et al. (2003) Stromal antigen targeting by a humanised monoclonal antibody: An early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 26(1):44-48.
59. Narra K, et al. (2007) Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol Ther 6(11):1691-1699.
60. Eager RM, et al. (2009) Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 21(6):464-472.
61. Kraman M, et al. (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330(6005):827-830.
62. Studeny M, et al. (2004) Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96(21): 1593-1603.
63. Yata Y, et al. (2003) DNase I-hypersensitive sites enhance alpha1(I) collagen gene expression in hepatic stellate cells. Hepatology 37(2):267-276.
64. Singh S, Ross SR, Acena M, Rowley DA, Schreiber H (1992) Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. JExp Med 175(1):139-146.
65. Dubey P, et al. (1997) The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J Exp Med 185(4):695-705.
66. Rosenberg SA, et al. (1986) A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery 100(2):262-272.
67. Schindelin J, et al. (2012) Fiji: An open-source platform for biological-image analysis. Nat Methods 9(7):676-682.
68. Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL (2001) Physiological migration of hematopoietic stem and progenitor cells. Science 294(5548):1933-1936.